Antimicrobial resistance patterns of MDR *Staphylococcus aureus* clinical isolates involved in the lower respiratory tract infections in Egypt

Salma Abdelaziz*, Khaled M. Aboshanab, Mahmoud A. Yassien, Nadia A. Hassouna

Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt

ABSTRACT

Resistance of *Staphylococcus* (*S.*) *aureus* to the currently used antimicrobials has risen dramatically in the past years creating a medical challenge as therapeutic options became very limited. This study aimed to screen and detect the prevalence of some antimicrobial-resistant genes of *S. aureus* clinical isolates recovered from patients suffering lower respiratory tract infections (LRTI) in Egypt. A total of 231 bacterial isolates were recovered from sputum and bronchoalveolar lavage specimens obtained from patients with LRTI. Thirty-seven isolates (16%) were identified as *S. aureus* where seventeen isolates (46%) showed resistance to ten or more antimicrobials. The antimicrobial susceptibility testing revealed that all the tested isolates were sensitive to vancomycin and linezolid (0%), however, the lowest resistance was observed to doxycycline (3%), and the highest resistance was observed to ciprofloxacin (51%). Sixteen isolates (43%) were found resistant to cefoxitin and harbored the mecA gene (100%). However, the mepA gene was detected in only 12 isolates (75%). Extended-spectrum β-lactamase (ESBL) including, *ctx-m*, *shv* and *tem* and the *aac(6’)-Ib* genes, were detected in 10 (62%) and 8 (50%) isolates, respectively. None of the carbapenem-resistant genes including *kpc*, *imp*, *vim*, *ndm*, and *oxa*, were detected in any isolate. Multiple drug resistance (MDR) is a major health concern limiting the use of common antimicrobials in therapy. Thus, new national guidelines, as well as infection control strategies including antibiotic stewardship, must be implemented in the Egyptian hospitals to limit further spread of antimicrobial resistance.

Keywords: Lower respiratory tract infections; multiple drug-resistant; *Staphylococcus aureus*; extended-spectrum β-lactamase; ESBLs; MDR

*Correspondence* | Salma Abdelaziz; Department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt. Email: salma.mostafa87@pharm.asu.edu.eg

Citation | Abdelaziz S, Aboshanab KM, Yassien MA, Hassouna NA. 2019. Antimicrobial resistance patterns of MDR *Staphylococcus aureus* clinical isolates involved in the lower respiratory tract infections in Egypt. Arch Pharm Sci ASU 3(2):294-304

DOI: [10.21608/APS.2019.17391.1014](https://doi.org/10.21608/APS.2019.17391.1014)

Print ISSN: 2356-8380. Online ISSN: 2356-8399.

Received 26 September 2019. Accepted 16 October 2019.

Copyright: ©2019 Abdelaziz et al. This is an open-access article licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Published by: Ain Shams University, Faculty of Pharmacy

1. INTRODUCTION

LRTIs are considered the leading cause of death due to infections and the fifth overall leading cause of death [1]. Although *S. aureus* is considered an uncommon cause of community-acquired pneumonia, it is a frequent cause of healthcare encountered pneumonia, accounting for 20-40% of these infections [2]. Treatment of *S. aureus* presents a therapeutic challenge as the organism has a remarkable ability to develop resistance. Penicillin was once recommended for treatment of *S. aureus* but resistance rose dramatically and 80% of the hospital-acquired
Over the years new β-lactamases have emerged and variants of existing enzymes have developed. They are called extended-spectrum β-lactamases (ESBL) due to their enhanced spectrum of activity. They include variants of TEM-1, SHV-1, CTX-M, and others [10]. Carbapenems were introduced to overcome the ESBL-producing bacteria, however, shortly afterward bacteria could produce carbapenemases making the therapeutic options very limited [11]. Examples of reported carbapenemases include KPC, IMP, NDM, VIM, and variants of OXA-48 [12]. Luckily, carbapenemases are only reported in Gram-negative bacteria and none are yet reported in S. aureus or any Gram-positive bacteria in literature.

Several experimental data have well documented the role of the multidrug efflux pumps to develop a low level of bacterial resistance to antimicrobials; however, they are a major culprit in the appearance of MDR phenotypes as they can extrude multiple unrelated compounds [13]. There are five families of MDR efflux pumps; they differ according to their structure and energy requirements. They are called adenosine-triphosphate (ATP)-binding cassette (ABC) superfamily, the major facilitator superfamily (MFS), the multidrug and toxic compound extrusion (MATE) family, the small multidrug resistance (SMR) family and the resistance-nodulation-cell division (RND) superfamily [14].

Therefore, this study aimed to elucidate the antimicrobial-resistant profiles of some S. aureus clinical isolates recovered from patients suffering from LRTI in Egypt as well as detection of most important antimicrobial-resistant genes that are
commonly involved in the resistance to the common antimicrobial agents used in the treatment of staphylococcal infections.

2. MATERIALS AND METHODS

2.1. Microorganisms

A total of 231 clinical bacterial isolates were obtained during the period from January 2016 to May 2017 from the microbiology laboratory at Al-Demerdash Hospital, Cairo, Egypt. These isolates were recovered from specimens collected from patients suffering from acute pneumonia. Specimens included sputum collected from either outpatients or patients requiring hospitalization. Only patients who did not receive previous antimicrobial treatment were included in the study. The isolates were identified microscopically by Gram stain and biochemically by catalase and coagulase tests [15]. They were further purified by streaking on the surface of fresh mannitol salt agar plates. For short term preservation, the isolates were cultured monthly on fresh nutrient agar slants and kept at 4 °C. For long term preservation, glycerol stocks were prepared and stored at -80 °C. The whole study was approved by the Faculty of Pharmacy, Ain Shams University Research Ethics Committee (ENREC-ASU-Nr. 94) where both informed and written consent were obtained from patients or parents of patients after explaining the study purpose.

2.2. Antimicrobial Susceptibility Test

The antimicrobial susceptibilities were determined by the disk diffusion method on Mueller Hinton agar plates as recommended by the clinical and laboratory standard institute (CLSI) [16]. Disks were obtained from Oxoid®, UK and Bioanalyse®, Turkey. The tested antimicrobials were: amikacin (30 µg), gentamicin (10 µg), tobramycin (10 µg), amoxicillin (25 µg), amoxicillin/clavulanic acid (20/10 µg), cefadroxil (30 µg), cefuroxime (30 µg), cefoxitin (30 µg), cefotaxime (30 µg), cefepime (30 µg), meropenem (10 µg), vancomycin (30 µg), linezolid (30 µg), ciprofloxacin (5 µg), levofloxacin (5 µg), doxycycline (30 µg), tetracycline (30 µg), trimethoprim/sulfamethoxazole SXT (1.25/23.75 µg), azithromycin (15 µg), clarithromycin (15 µg), erythromycin (15 µg) and clindamycin (2 µg). S. aureus ATCC 25923 was used for the quality control of this experiment according to CLSI guidelines [16].

2.3. Phenotypic Detection of MRSA Isolates

MRSA isolates harboring the mecA-coding gene could be easily detected using cefoxitin (30 µg) disks. Cefoxitin is used as a surrogate for mecA-mediated oxacillin or methicillin resistance [16]. The test was done according to the CLSI guidelines. Freshly (18 to 24 h incubation period) isolated colonies of the test isolate were suspended in isotonic saline to match the turbidity of 0.5 McFarland standard suspension. Then, the surface of an MHA plate was swabbed in three different directions and along the rim of the plate. A disk containing 30 µg of cefoxitin was placed on the surface of the plate and gently pressed. The plate was incubated at 37 °C for 16 to 18 h. Isolates having inhibition zone (IZ) diameters with cefoxitin ≤ 21 mm are considered mecA positive. These isolates were selected for further study.

2.4. Detection of Selected Resistance Genes

Genomic and plasmid DNA was extracted from the MDR isolates using the purchased extraction kits according to the manufacturers' instructions. The genomic DNA was extracted using a Genomic DNA extraction Kit (Thermo Scientific, USA) and the plasmid DNA was extracted using the GeneJet plasmid miniprep kit (Thermo Scientific, USA). The extracted DNA was used as the template in the polymerase chain reaction (PCR) amplification cycles. The PCR
Antimicrobial resistance patterns of MDR Staphylococcus aureus clinical isolates

products were detected by agarose gel electrophoresis (AGE) [17]. The primers (oligonucleotides) used to amplify the studied resistance genes are listed in Table 1.

Table 1: Oligonucleotides used in this study, their target resistance genes, their expected product sizes (bp), their references and the used annealing temperatures (T_a).

| Target gene | Primer sequence (5’→3’) | Size (bp) | T_a (°C) | Reference |
|-------------|--------------------------|-----------|----------|-----------|
| bla_KPC     | P_t GGTTATGCGTTATATTCGCC TGCAGTGCTCTACAGAAAACC | 1100      | 50       | [18]      |
| bla_IMP     | P_t CTACATGACCAGCCTGTCGCTGTC | 748       | 50       | [19]      |
| bla_VIM     | P_t GGTGGTTGAGATCGTTGTACCTAATGAGTGG | 621       | 50       | [20]      |
| bla_NDM     | P_t ACCCAGTGCTCACAGGATGTAACACACCG | 438       | 50       | [21]      |
| bla_OXA     | P_t CGGTAGTTGATGGTACAG | 550       | 50       | [22]      |
| bla_CTX-M   | P_t TTGCGATGCTCATACAGGATGTAACACACCG | 438       | 50       | [23]      |
| bla_SIV     | P_t CGGGCGATATCGTTGGTCGCA | 867       | 50       | [24]      |
| bla_TEM     | P_t ATGAGTATTCAACATTTCCG | 867       | 50       | [25]      |
| aac(6’)-Ib  | P_t CGGGCGATATCGTTGGTCGCA | 358       | 50       | [26]      |
| aac(6’)-Ib-cr | AAAATCGATGTTAAGGTTGTCGCA | 533       | 50       | [27]      |
| mecA        | P_t AGTTCTGGAGTACCCGAATTC | 718       | 50       | [28]      |
| mepA        | P_t TCAACTGTCAAGAGCATACAG | 854       | 50       | [29]      |

Some PCR products were purified using the GeneJET purification kit (Fermentas, USA) at Sigma Scientific Services Company, Egypt. Then, they were sent for sequencing at GATC Biotech Company (Germany) through Sigma Scientific Services Company (Egypt) by the use of ABI 3730xl DNA Sequencer. They were sequenced from both the forward and reverse directions, and the obtained ABI sequence files were assembled into the final contigs using Staden Package program version 3 (http://staden.sourceforge.net/).

The resulted contigs were analyzed for the detection of ORFs using FramePlot 4.0 beta (http://nocardia.nih.go.jp/fp4/). The ORFs of the nucleotide and amino acid sequences were analyzed using BLASTn and BLASTp online tools, respectively. The resulted proteins were aligned with other homologous proteins from the GenBank database using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). Finally, some genes were submitted in the GenBank database and their corresponding accession codes were obtained. (NCBI accession code for mecA gene: MK341125. NCBI accession code for mepA: MK341122).

2.5. Statistical Analysis

Statistical analysis of the data was performed using IBM SPSS Statistics software for Windows v. 20.0 (IBM Corp., USA). Qualitative data were expressed as frequency and percentage. A chi-
square test was used to compare categorical variables. All tests were two-tailed, and $P$-value < 0.05 was considered as statistically significant.

3. RESULTS

A total of 231 bacterial isolates were recovered from patients suffering from acute pneumonia. Thirty-seven isolates (16%) were identified as *S. aureus*; their antibiogram analysis is clarified in Table 2. From which, 18 isolates (48%) were resistant to ≥3 classes of antimicrobial agents and considered to be MDR [27]. Seventeen isolates (94%) of the MDR isolates were resistant to ten or more antimicrobials. Sixteen isolates overall (43%) had IZ diameters with cefoxitin ≤ 21 mm and were considered to be MRSA isolates, these isolates were selected for further study. The antimicrobial susceptibility testing showed that all the tested isolates were sensitive to vancomycin and linezolid (0%). Fig. 1 shows the approximate percentage of resistance to the different tested antimicrobial agents among the *S. aureus* isolates.

Table 2 Antibiogram analysis of the collected *S. aureus* isolates (n= 37)

| Antimicrobial Agent (conc. 'µg'/disc) | Sensitive | Intermediate | Resistant |
|--------------------------------------|-----------|--------------|-----------|
|                                      | n° %      | n° %         | n° %      |
| 1 Amoxicillin (25)                   | 20 54     | 0 0          | 17 46     |
| 2 Coamoxiclav (30)                   | 21 57     | 0 0          | 16 43     |
| 3 Cefadroxil (30)                    | 20 54     | 2 5          | 15 41     |
| 4 Cefuroxime (30)                    | 20 54     | 0 0          | 17 46     |
| 5 Cefoxitin (30)                     | 21 57     | 0 0          | 16 43     |
| 6 Cefotaxime (30)                    | 20 54     | 1 3          | 16 43     |
| 7 Cefepime (30)                      | 21 57     | 0 0          | 16 43     |
| 8 Meropenem (10)                     | 24 65     | 2 5          | 11 30     |
| 9 Doxycyline (30)                    | 31 84     | 5 13         | 1 3       |
| 10 Tetracycline (30)                 | 22 59     | 1 3          | 14 38     |
| 11 Ciprofloxacin (5)                 | 18 49     | 0 0          | 19 51     |
| 12 Levofloxacin (5)                  | 18 49     | 1 2          | 18 49     |
| 13 Amikacin (30)                     | 26 70     | 2 6          | 9 24      |
| 14 Gentamicin (10)                   | 19 51     | 1 3          | 17 46     |
| 15 Tobramycin (10)                   | 19 51     | 0 0          | 18 49     |
| 16 Cotrimoxazole (25)                | 29 78     | 1 3          | 7 19      |
| 17 Azithromycin (15)                 | 19 51     | 0 0          | 18 49     |
| 18 Clarithromycin (15)               | 19 51     | 1 3          | 17 46     |
| 19 Erythromycin (15)                 | 19 51     | 0 0          | 18 49     |
| 20 Clindamycin (2)                   | 24 65     | 0 0          | 13 35     |
| 21 Vancomycin (30)                   | 37 100    | 0 0          | 0 0       |
| 22 Linezolid (30)                    | 37 100    | 0 0          | 0 0       |

All MRSA isolates (100%) harbored the *mecA* gene responsible for the production of altered PBP2a (NCBI accession code: MK341125). Twelve isolates (75%) harbored the *mepA* multidrug efflux pump gene (NCBI accession code: MK341122). Ten isolates (62%) harbored one or more of the ESBL genes; *ctx-, m, shv* and/or *tem*. The *aac(6’)-Ib* gene was detected in 8 isolates (50%). None of the carbapenem-resistant genes; *kpc, imp, vim, ndm* and/or *oxa*, were detected in any isolate. Figs. 2 and 3 show the agarose electrophoresis gels of the detected resistance genes. Table 3 shows the resistance profile of the MRSA isolates along with the detected resistance genes.
Antimicrobial resistance patterns of MDR Staphylococcus aureus clinical isolates

**Fig. 1.** Approximate percentage of resistance to the different tested antimicrobial agents among the *S. aureus* isolates (n=37)

**Fig. 2.** Agarose gel electrophoresis of the PCR products of the resistance genes isolated from MRSA isolates 43. Lanes: 1, 550 bp PCR product of *bla*<sub>CTX-M</sub>; 2, 867 bp PCR product of *bla*<sub>SHV</sub>; 3, 867 bp PCR product of *bla*<sub>TEM</sub>; 4, 358 bp PCR product of *aac(6')-Ib*

**Fig. 3.** Agarose gel electrophoresis of PCR products of *mepA* gene (718 bp) and *mecA* gene (533 bp) from different MRSA isolates. Lanes: 1, isolate 26; 2, isolate 43; 3, isolate 130; 4, isolate 141; 5, 100bp DNA ladder (Thermo Scientific, USA); 6, isolate 32; 7, isolate 116; 8, isolate 135 and 9, isolate 162
Table 3. MRSA isolates resistance profile and the detected resistance genes

| Antimicrobial Agent/ Gene | Isolate Code |
|---------------------------|--------------|
|                           | S26 | S32 | S36 | S43 | S116 | S121 | S125 | S130 | S131 | S135 | S137 | S141 | S160 | S161 | S162 | S163 |
| Amoxicillin               | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Coamoxiclav               | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cefadroxil                | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cefuroxime                | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cefotaxime                | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cefepime                  | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Meropenem                 | R   | I   | R   | R   | R    | R    | R    | S    | S    | I    | R    | S    | R    | R    | R    | R    | R    | R    |
| Doxycycline               | S   | I   | S   | R   | I    | S    | S    | I    | S    | S    | S    | I    | S    | S    | S    | S    | S    |
| Tetracycline              | R   | R   | S   | R   | S    | R    | R    | R    | I    | S    | R    | R    | S    | R    | S    | R    | S    |
| Ciprofloxacin             | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Levofloxacin              | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Amikacin                  | R   | R   | S   | R   | S    | R    | R    | R    | I    | S    | I    | R    | S    | S    | R    | R    | R    |
| Gentamicin                | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Tobramycin                | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cotrimoxazole             | S   | S   | R   | S   | S    | S    | R    | S    | R    | S    | S    | S    | R    | S    | S    |
| Azithromycin              | R   | R   | R   | S   | R    | S    | R    | S    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Clarithromycin            | R   | R   | R   | S   | R    | S    | R    | S    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Erythromycin              | R   | R   | R   | S   | R    | S    | R    | S    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Clindamycin               | R   | R   | S   | S   | R    | S    | R    | S    | R    | R    | R    | R    | R    | R    | R    | R    |
| Cefoxitin                 | R   | R   | R   | R   | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    | R    |
| Vancomycin                | S   | S   | S   | S   | S    | S    | S    | S    | S    | S    | S    | S    | S    | S    | S    |
| Linezolid                 | S   | S   | S   | S   | S    | S    | S    | S    | S    | S    | S    | S    | S    | S    | S    |
| meca                      | +   | +   | +   | +   | +    | +    | +    | +    | +    | +    | +    | +    | +    |
| mepA                      | +   | +   | -   | +   | +    | +    | +    | +    | +    | +    | -    | +    |
| aac6'-Ib                  | +   | +   | -   | +   | -    | -    | +    | +    | -    | +    | +    | +    |
| ctx-m                     | +   | -   | +   | +   | -    | -    | +    | +    | -    | +    | +    | +    |
| shv                       | +   | -   | +   | -   | -    | -    | -    | -    | -    | -    | +    | +    |
| tem                       | -   | -   | +   | +   | -    | -    | -    | -    | -    | -    | -    | -    |
| kpc                       | -   | -   | -   | -   | -    | -    | -    | -    | -    | -    | -    | -    |
| imp                       | -   | -   | -   | -   | -    | -    | -    | -    | -    | -    | -    | -    |
| vim                       | -   | -   | -   | -   | -    | -    | -    | -    | -    | -    | -    | -    |
| ndm                       | -   | -   | -   | -   | -    | -    | -    | -    | -    | -    | -    | -    |
| oxa                       | -   | -   | -   | -   | -    | -    | -    | -    | -    | -    | -    | -    |
Antimicrobial resistance patterns of MDR Staphylococcus aureus clinical isolates

Statistical analysis has shown a statistically significant association between the detection of resistance genes and the phenotypic antimicrobial resistance. Calculation of Pearson Chi-square value showed a significant association between the presence of the multidrug efflux pump; MepA, and resistance to tetracycline and sulfonamides. Also, there was a significant association between the coexistence of tem and aac(6')-Ib genes and shv and aac(6')-Ib genes.

4. DISCUSSION

This study aimed to elucidate the antimicrobial-resistant profiles of some S. aureus clinical isolates involved in acute pneumonia and to detect the most common antimicrobial-resistant genes. Comparing our results with a previous Egyptian study [28], our findings showed a similar prevalence of S. aureus isolated from RTIs. Moreover, a similar, prevalence was also observed with another recent study conducted in Egypt on patients suffering from pneumonia [29]. Similarly, none of the isolates were resistant to vancomycin and similar resistance was observed to macrolides. However, we observed a much lower prevalence of MRSA isolates; 43% compared to 81% in the previously mentioned study [29]. Much lower prevalence of MRSA isolates was also observed when comparing with a third Egyptian study [30]; 43% compared to 77%. While similar resistance was observed with macrolides and ciprofloxacin. On the other hand, our MRSA results and resistance patterns were found similar to another Egyptian study conducted in Upper Egypt [31].

Comparing our results with a systematic review on antimicrobial resistance in African countries [32] revealed a similar prevalence of S. aureus isolates; 16% in our study compared to 21.5% in the review. However, a much lower prevalence of MRSA isolates was reported in the review; 10.4% compared to 43% in our study. The review reported much higher resistance to amoxicillin, cotrimoxazole, and doxycycline; 78%, 66%, 55% respectively. On the other hand, much lower resistance was reported in the same review to amikacin, cefotaxime, ciprofloxacin, clindamycin, co-amoxiclav, erythromycin, gentamicin, levofloxacin; 3%, 28%, 21%, 11%, 23%, 33%, 18%, 5%, respectively. Similar resistance was reported to cefuroxime and tetracycline. Our study did not detect any isolate resistant to vancomycin as compared to this review which reported 2% vancomycin resistance. The review included more than 144 studies and 149,000 samples from patients all across Africa. Different resistance patterns to the tested antimicrobial agents can be explained by the fact that various patterns of prescribing antimicrobials among the countries will inevitably lead to different resistance profiles.

We compared our results with other developing African countries as we share common practices that lead to the spread of antimicrobial resistance. Resistance in developing countries is attributed to complex factors as the self-prescribing of antimicrobials by the patients, the unnecessary prescribing of antimicrobials by the physicians, the relatively poor quality of the available antimicrobials along with the overall poor hygienic pursuits [33]. This leads to comparatively higher levels of resistance compared with the developed countries as well as the extensive spread of MDR isolates making the therapeutic options severely limited. However, antimicrobial resistance is an issue that concerns all countries regardless of their development level; as resistant pathogens easily spread between countries and do not respect border barriers [32].

All of the MRSA isolates were resistant to penicillins and cephalosporins. Besides, all of them (100%) harbored the mecA gene responsible for the production of altered PBP2a; this strongly highlights its importance to develop
resistance against methicillin and the other members. The wide prevalence of mepA multidrug efflux pump gene (75%) suggests its major role in the development of MDR S. aureus. None of the carbapenem-resistant genes; kpc, imp, vim, ndm and/or oxa, were detected in any isolate and this finding was following other studies that were undertaken worldwide. All amikacin resistant isolates harbored the aac(6')-Ib gene which plays a major role in resistance to aminoglycosides. Ten isolates (62%) harbored one or more of the ESBL genes; ctx-m, shv and/or tem.

In conclusion, accurate local periodic reports of the resistance pattern are of great importance to provide the healthcare practitioners with a clear picture and to guide them to more effective antimicrobial prescription patterns. Guided prescription policies must be implemented nationwide to limit the further spread of MDR organisms. Public awareness should also be addressed to limit the high level of antimicrobials misuse and to highlight the importance of hygienic practices.

Declarations

Ethics approval and consent to participate

The whole study was approved by the Faculty of Pharmacy, Ain Shams University Research Ethics Committee (ENREC-ASU-Nr. 94).

Consent to publish

Both informed and written consents were obtained from patients or parents of patients after explaining the study purpose

Availability of data and materials

All data generated or analyzed during this study are included in this published article in the main manuscript.

Competing interests

The authors declare that no competing interests exist

Funding Statement

No funding source was received.

Authors' contributions

The manuscript was drafted and written by SA, KMA and revised by KMA, MAY and NAH. All authors have read and approved the final manuscript.

Acknowledgment

The authors would like to acknowledge all colleagues in the Microbiology and Immunology Department, Ain Shams University for their support.

5. REFERENCES

1. Global Burden of Disease Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis, 2017; 17(11): 1133–61. https://doi.org/10.1016/S1473-3099(17)30396-1

2. Leem AY, Jung WJ, Kang YA, Park SC, Kim YJ, Hwang ED et al. Comparison of Methicillin-Resistant Staphylococcus aureus Community-Acquired and Healthcare-Associated Pneumonia. Yonsei Med J, 2014; 55(4): 967–74. https://doi.org/10.3349/ymj.2014.55.4.967

3. Reddy PN, Srirama K, Dirisala VR. An Update on Clinical Burden, Diagnostic Tools, and Therapeutic Options of Staphylococcus aureus. Infect Dis (Auckl), 2017; 10:1-15. https://doi.org/10.1177/1179916117703999

4. Harkins CP, Pichon B, Doumith M, Parkhill J, Westh H, Tomasz A, et al. Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. Genome Biol, 2017; 18:130-41. https://doi.org/10.1186/s13059-017-1252-9

5. Ferrara AM. Treatment of hospital-acquired pneumonia caused by methicillin-resistant
Antimicrobial resistance patterns of MDR Staphylococcus aureus clinical isolates

Staphylococcus aureus. Int J Antimicrob Agents, 2007; 30(1): 19–24. https://doi.org/10.1016/j.ijantimicag.2007.02.011

6. Reygaert WC. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol, 2018; 4(3): 482–501. https://doi.org/10.3934/microbiol.2018.3.482

7. Dolejska M, Papagiannitsis CC. Plasmid-mediated resistance is going wild. Plasmid, 2018; 99: 99–111. https://doi.org/10.1016/j.plasmid.2018.09.010

8. Smith CA, Bhattacharya M, Toth M, Stewart NK, Vakulenko SB. Aminoglycoside resistance profile and structural architecture of the aminoglycoside acetyltransferase AAC(6′)-I'm. Microb Cell, 2017;4(12): 402–10. https://doi.org/10.15698/mic2017.12.602

9. Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. Biomed Res Int, 2018; 1-14. https://doi.org/10.1155/2018/9519718

10. Munita JM, Arias CA. Mechanisms of Antibiotic Resistance. Microbiol Spectr, 2016; 4(2): 1-37. https://doi.org/10.1128/microbiolspec.VMBF-0016-2015

11. Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Med Sci (Basel). 2017; 6(1): 1-28. https://doi.org/10.3390/medsci6010001

12. Santajit S, Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed Res Int 2016;1-8. https://doi.org/10.1155/2016/2475067

13. Costa SS, Viveiros M, Amaral L, Couto I. Multidrug Efflux Pumps in Staphylococcus aureus: an Update. Open Microbiol J, 2013; 7: 59–71. https://doi.org/10.2174/1874285801307010059

14. Du D, Wang-Kun X, Neuberger A, Veen HW van, Pos KM, Piddock LJV, et al. Multidrug efflux pumps: structure, function, and regulation. Nat Rev Microbiol, 2018; 16(9): 523–39. https://doi.org/10.1038/s41579-018-0048-6

15. Cheesbrough M. District Laboratory Practice in Tropical Countries Part2 Cheesbrough M. District laboratory practice in tropical countries. Vol. 2. New York: Cambridge University Press; 2006. New York: Cambridge University Press, 2006. ISBN: 978-0-511-34842-6

16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute, USA, 2016. ISBN: 1-56238-924-6

17. Sambrook JJ, Russell DDW. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press, USA, 2001. ISBN: 0-87969-577-3

18. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother, 2001; 45(4): 1151–61. https://doi.org/10.1128/AAC.45.4.1151-1161.2001

19. Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S et al. PCR detection of metallo-beta-lactamase gene (blaIMP) in Gram-negative rods resistant to broad-spectrum beta-lactams. J Clin Microbiol, 1996; 34(12): 2909–13. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC229432/

20. Poirel L, Naas T, Nicolas D, Collet L, Bellais S, Cavallo J-D et al. Characterization of VIM-2, a Carbapenem-Hydrolyzing Metallo-beta-Lactamase and Its Plasmid- and Integron-Borne Gene from a Pseudomonas aeruginosa Clinical Isolate in France. Antimicrob Agents Chemother, 2000; 44(4): 891–7. https://doi.org/10.1128/aac.44.4.891-897.2000

21. Nordmann P, Poirel L, Carrër A, Toleman MA, Walsh TR. How To Detect NDM-1 Producers. J Clin Microbiol, 2011; 49(2): 718–21. https://doi.org/10.1128/JCM.01773-10

22. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis, 2011; 70(1): 119–23. https://doi.org/10.1016/j.diagmicrobio.2010.12.002

23. Bonnet R, Dutour C, Sampaio JL, Chanal C, Sirot D, Labia R et al. Novel cefotaximase (CTX-M-16)
with increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob Agents Chemother, 2001; 45(8): 2269–75. https://doi.org/10.1128/AAC.45.8.2269-2275.2001

24. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41(3): 647–653. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC163766/

25. Pournajaf A, Ardehili A, Goudarzi L, Khodabandeh M, Namirani T, Abbaszadeh H. PCR-based identification of methicillin-resistant Staphylococcus aureus strains and their antibiotic resistance profiles. Asian Pac J Trop Biomed, 2014; 4(1): S293–7. https://doi.org/10.12980/APJTB.4.2014C423

26. Couto I, Costa SS, Viveiros M, Martins M, Amaral L. Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J Antimicrob Chemother, 2008; 62(3): 504–13. https://doi.org/10.1093/jac/dkn217

27. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012; 18(3): 268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x

28. El-Kased RF. Natural antibacterial remedy for respiratory tract infections. Asian Pacific J Tropical Biomedicine, 2016; 6(3): 270–4. https://doi.org/10.1016/j.apjtb.2015.12.002

29. El-Sokkary RH, Ramadan RA, El-Shabrawy M, El-Korashi LA, Elhawary A, Embarak S, et al. Community-acquired pneumonia among adult patients at an Egyptian university hospital: bacterial etiology, susceptibility profile, and evaluation of the response to initial empiric antibiotic therapy. Infect Drug Resist, 2018; 11: 2141–50. https://doi.org/10.2147/IDR.S182777

30. Ahmed S, Tolba S, Al Zawahry Y. Evaluation of the Role Of bla Genes in Beta-Lactam and Methicillin-Resistant Staphylococcus aureus. Egypt J Bot, 2019; 59(1): 29-38. https://dx.doi.org/10.21608/ezjbo.2018.4221.1187

31. Hassan AT, Mohamed SAA, Mohamed MSE, El-Mokhtar MA. Acute exacerbations of chronic obstructive pulmonary disease: etiological bacterial pathogens and antibiotic resistance in Upper Egypt. Egypt J Bronchology, 2016; 10(3): 283–90. https://doi.org/10.4103/1687-8426.193640

32. Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ et al. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis, 2017; 17(1): 616. https://doi.org/10.1186/s12879-017-2713-1

33. Chokshi A, Sifri Z, Cennimo D, Horng H. Global Contributors to Antibiotic Resistance. J Glob Infect Dis, 2019; 11(1): 36–42. https://doi.org/10.4103/jgid.jgid_110_18